These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25786743)

  • 1. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
    Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
    Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Supporting Role of (18)FDG-PET in Patients with Neuroendocrine Tumors.
    Howe JR
    Ann Surg Oncol; 2015 Jul; 22(7):2107-9. PubMed ID: 25777088
    [No Abstract]   [Full Text] [Related]  

  • 5. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
    Garin E; Le Jeune F; Devillers A; Cuggia M; de Lajarte-Thirouard AS; Bouriel C; Boucher E; Raoul JL
    J Nucl Med; 2009 Jun; 50(6):858-64. PubMed ID: 19443590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of FDG-PET in the assessment of survival prognosis in melanoma.
    Pleiss C; Risse JH; Biersack HJ; Bender H
    Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Application of 68Ga-Somatostatin Analog and 18F-FDG PET/CT for Bone Metastasis from Neuroendocrine Tumors.
    Bai L; Xu J; Xu X; Zhang J; Liu X; Hu S; Chen J; Song S
    Neuroendocrinology; 2024; 114(8):775-785. PubMed ID: 38824926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Usefulness of
    Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
    Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
    Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
    Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
    Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
    J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
    Panagiotidis E; Bomanji J
    PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
    J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.